Chevy Chase Trust Holdings LLC Has $27.12 Million Stock Position in Becton, Dickinson and Company $BDX

Chevy Chase Trust Holdings LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.3% during the second quarter, Holdings Channel reports. The firm owned 157,437 shares of the medical instruments supplier’s stock after buying an additional 548 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Becton, Dickinson and Company were worth $27,119,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $27,000. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC boosted its holdings in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $31,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler reissued a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $205.40.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders have sold 1,838 shares of company stock valued at $348,392. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $189.20 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a 50 day moving average price of $190.60 and a 200 day moving average price of $184.92. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The stock has a market capitalization of $54.23 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 1.45 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.